Results 31 to 40 of about 532,597 (317)
The Renewal of Cancer Immunotherapy
, 2023 Cancer immunotherapy embraces many current, promising therapeutic approaches to eradicate tumors by activating host antitumor activity [...
Jenny Bulgarelli +3 more
core +1 more source
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Journal for ImmunoTherapy of Cancer, 2019 Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith +40 more
doaj +1 more source
The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration
Nature Communications, 2023 As the primary site of T-cell development, the thymus dictates immune competency of the host. The rates of thymus function are not constant, and thymus regeneration is essential to restore new T-cell production following tissue damage from environmental ...
Emilie J. Cosway +7 more
doaj +1 more source
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection [PDF]
, 1987 We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in ...
Reddehase, Matthias J. +9 more
core +1 more source
Intralymphatic immunotherapy [PDF]
World Allergy Organization Journal, 2015 Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to achieve amelioration of symptoms. Intralymphatic vaccination can maximize immunogenicity and hence efficacy.
Gabriela Senti, Thomas M Kündig
openaire +3 more sources
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
OncoImmunology, 2023 BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory ...
Maite Alvarez +16 more
doaj +1 more source
Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
, 2022 SIMPLE SUMMARY: Hepatocellular carcinoma is one of the most lethal malignancies, having a significantly poor prognosis. Immunotherapy, as an emerging tumor treatment option, provides new hope for many cancer patients.
Tian, Bao-Wen +11 more
core +1 more source
OncoImmunology, 2018 Memory CD8+ T cell responses have the potential to mediate long-lasting protection against cancers. Resident memory CD8+ T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens.
Felipe Gálvez-Cancino +13 more
doaj +1 more source
, 2020 In the last few decades, cancer immunotherapy becomes an important tactic for cancer treatment. However, some immunotherapy shows certain limitations including poor therapeutic targeting and unwanted side effects that hinder its use in clinics. Recently,
Tilahun Ayane Debele +2 more
core +1 more source
Immunotherapy in Advanced Biliary Tract Cancers
, 2021 Biliary tract cancers are rare tumors with a poor prognosis. Two-thirds of these primary liver malignancies are diagnosed at advanced stages where therapeutic options are limited.
Michel Ducreux +5 more
core +1 more source